149 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NBIX Neurocrine Biosciences, Inc. $117.38 $10.62B Buy
Article Searches
CTLT or NBIX: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/359783/ctlt-or-nbix-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-359783 Mar 15, 2019 - CTLT vs. NBIX: Which Stock Is the Better Value Option?
Orbimed Advisors Llc Buys Guardant Health Inc, CVS Health Corp, Celgene Corp, Sells Jazz ... http://www.gurufocus.com/news/831119/orbimed-advisors-llc-buys-guardant-health-inc-cvs-health-corp-celgene-corp-sells-jazz-pharmaceuticals-plc-alexion-pharmaceuticals-inc-bristolmyers-squibb-company Mar 12, 2019 - Orbimed Advisors Llc Buys Guardant Health Inc, CVS Health Corp, Celgene Corp, Sells Jazz Pharmaceuticals PLC, Alexion Pharmaceuticals Inc, Bristol-Myers Squibb Company, Stocks: CELG,ISRG,BHC,CNC,NBIX,DCPH,GH,CVS,DXCM,MYOK,THC,I, release date:Mar 11, 2019
Neurocrine Dives Into Gene Therapy https://seekingalpha.com/article/4244858-neurocrine-dives-gene-therapy?source=feed_sector_healthcare Feb 27, 2019 - Neurocrine recently nabbed a deal with Voyager Therapeutics for a gene therapy program. The program is well within Neurocrine's scope of movement disorders, as it targets Parkinson's disease. The deal
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now? http://www.zacks.com/stock/news/353865/ctlt-vs-nbix-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-353865 Feb 12, 2019 - CTLT vs. NBIX: Which Stock Is the Better Value Option?
Two Catalysts For Axovant Sciences In March https://seekingalpha.com/article/4239710-two-catalysts-axovant-sciences-march?source=feed_sector_healthcare Feb 11, 2019 - AXON has confirmed initial data are coming from two trials in March.I take a look at AXO-Lenti-PD and previous data with ProSavin.I take a look at other data with Parkinson's disease gene therapies.I
Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018 http://www.gurufocus.com/news/812677/neurocrine-biosciences-inc-nbix-files-10k-for-the-fiscal-year-ended-on-december-31-2018 Feb 08, 2019 - Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: NBIX, release date:Feb 08, 2019
Neurocrine Biosciences, Inc. 2018 Q4 - Results - Earnings Call Slides https://seekingalpha.com/article/4238721-neurocrine-biosciences-inc-2018-q4-results-earnings-call-slides?source=feed_sector_healthcare Feb 06, 2019 - The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2018 Q4 earnings call.
Neurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/05/neurocrine-biosciences-inc-nbix-q4-2018-earnings-c.aspx?source=iedfolrf0000001 Feb 05, 2019 - NBIX earnings call for the period ending December 31, 2018.
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4238397-neurocrine-biosciences-nbix-ceo-kevin-gorman-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 05, 2019 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2018 Earnings Conference Call February 5, 2019 4:30 PM ET Company Participants Kevin Gorman – Chief Executive Officer Jane Sorensen – Head-Investor Relati
Neurocrine Turns To Gene Therapy To Bolster Its Movement Disorder Franchise https://seekingalpha.com/article/4236612-neurocrine-turns-gene-therapy-bolster-movement-disorder-franchise?source=feed_sector_healthcare Jan 30, 2019 - Neurocrine has chosen to in-license some early-stage CNS gene therapy assets that could significantly build its movement disorder franchise down the line. Voyager's lead candidate targets restoring AA

Pages: 123456...15

Page 1>

Related Companies

Name Exchange Price Mkt Cap
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
QGEN Qiagen N.V. NYSE $37.42 $8.5B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
BLUE bluebird bio, Inc. NASDAQ $137.25 $7.43B
TECH Bio-Techne Corp NASDAQ $196.8 $7.43B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Neurocrine Biosciences
NBIX - Google Finance https://www.google.com/finance?q=NBIX Industry related info and international coverage Summary News
NBIX - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=NBIX Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options